NCCN Guidelines Insights: Prostate Cancer, Version 1.2021.
Publication
, Journal Article
Schaeffer, E; Srinivas, S; Antonarakis, ES; Armstrong, AJ; Bekelman, JE; Cheng, H; D'Amico, AV; Davis, BJ; Desai, N; Dorff, T; Eastham, JA ...
Published in: J Natl Compr Canc Netw
February 2, 2021
The NCCN Guidelines for Prostate Cancer address staging and risk assessment after a prostate cancer diagnosis and include management options for localized, regional, and metastatic disease. Recommendations for disease monitoring and treatment of recurrent disease are also included. The NCCN Prostate Cancer Panel meets annually to reevaluate and update their recommendations based on new clinical data and input from within NCCN Member Institutions and from external entities. This article summarizes the panel's discussions for the 2021 update of the guidelines with regard to systemic therapy for metastatic castration-resistant prostate cancer.
Duke Scholars
Altmetric Attention Stats
Dimensions Citation Stats
Published In
J Natl Compr Canc Netw
DOI
EISSN
1540-1413
Publication Date
February 2, 2021
Volume
19
Issue
2
Start / End Page
134 / 143
Location
United States
Related Subject Headings
- Risk Assessment
- Prostatic Neoplasms, Castration-Resistant
- Prostatic Neoplasms
- Oncology & Carcinogenesis
- Neoplasm Staging
- Neoplasm Metastasis
- Male
- Humans
- 4203 Health services and systems
- 3211 Oncology and carcinogenesis
Citation
APA
Chicago
ICMJE
MLA
NLM
Schaeffer, E., Srinivas, S., Antonarakis, E. S., Armstrong, A. J., Bekelman, J. E., Cheng, H., … Freedman-Cass, D. A. (2021). NCCN Guidelines Insights: Prostate Cancer, Version 1.2021. J Natl Compr Canc Netw, 19(2), 134–143. https://doi.org/10.6004/jnccn.2021.0008
Schaeffer, Edward, Sandy Srinivas, Emmanuel S. Antonarakis, Andrew J. Armstrong, Justin E. Bekelman, Heather Cheng, Anthony Victor D’Amico, et al. “NCCN Guidelines Insights: Prostate Cancer, Version 1.2021.” J Natl Compr Canc Netw 19, no. 2 (February 2, 2021): 134–43. https://doi.org/10.6004/jnccn.2021.0008.
Schaeffer E, Srinivas S, Antonarakis ES, Armstrong AJ, Bekelman JE, Cheng H, et al. NCCN Guidelines Insights: Prostate Cancer, Version 1.2021. J Natl Compr Canc Netw. 2021 Feb 2;19(2):134–43.
Schaeffer, Edward, et al. “NCCN Guidelines Insights: Prostate Cancer, Version 1.2021.” J Natl Compr Canc Netw, vol. 19, no. 2, Feb. 2021, pp. 134–43. Pubmed, doi:10.6004/jnccn.2021.0008.
Schaeffer E, Srinivas S, Antonarakis ES, Armstrong AJ, Bekelman JE, Cheng H, D’Amico AV, Davis BJ, Desai N, Dorff T, Eastham JA, Farrington TA, Gao X, Horwitz EM, Ippolito JE, Kuettel MR, Lang JM, McKay R, McKenney J, Netto G, Penson DF, Pow-Sang JM, Reiter R, Richey S, Roach Iii M, Rosenfeld S, Shabsigh A, Spratt DE, Teply BA, Tward J, Shead DA, Freedman-Cass DA. NCCN Guidelines Insights: Prostate Cancer, Version 1.2021. J Natl Compr Canc Netw. 2021 Feb 2;19(2):134–143.
Published In
J Natl Compr Canc Netw
DOI
EISSN
1540-1413
Publication Date
February 2, 2021
Volume
19
Issue
2
Start / End Page
134 / 143
Location
United States
Related Subject Headings
- Risk Assessment
- Prostatic Neoplasms, Castration-Resistant
- Prostatic Neoplasms
- Oncology & Carcinogenesis
- Neoplasm Staging
- Neoplasm Metastasis
- Male
- Humans
- 4203 Health services and systems
- 3211 Oncology and carcinogenesis